Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL931484

CN1CCCC1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.38
HRH3 Q9Y5N1 2/20 0.38
CYP1A2 P05177 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
CXCR2 P25025 1/20 0.35
LMNA P02545 1/20 0.34
MLYCD O95822 1/20 0.34
HIF1A Q16665 1/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
CHRM1 P11229 3/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
DPP4 P27487 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2265475 1.00 HRH4 (0.38) HRH4HRH3CYP1A2TDP1ALDH1A1
Trifluoroacetic Acid SCHEMBL2265470 1.00 HRH4 (0.38) HRH4HRH3CYP1A2TDP1ALDH1A1
N-Methylpiperidine SCHEMBL2071510 0.98 ALDH1A1 (0.38) HRH4HRH3CYP1A2TDP1ALDH1A1
N-Methylpiperidine SCHEMBL2072770 0.98 ALDH1A1 (0.38) HRH4HRH3CYP1A2TDP1ALDH1A1
Trifluoroacetic Acid SCHEMBL2265017 0.98 ALDH1A1 (0.38) HRH4HRH3CYP1A2TDP1ALDH1A1
N-Methylpiperidine SCHEMBL2071509 0.98 ALDH1A1 (0.38) HRH4HRH3CYP1A2TDP1ALDH1A1
Trifluoroacetic Acid SCHEMBL2265273 0.92 HRH4 (0.39) HRH4HRH3CYP1A2TDP1ALDH1A1
Trifluoroacetic Acid SCHEMBL23292174 0.90 CYP1A2 (0.46) HRH4HRH3CYP1A2TDP1ALDH1A1
Trichloroacetic Acid SCHEMBL7710317 0.80 ALDH1A1 (0.50) HRH3CYP1A2TDP1ALDH1A1HTT
Methylpiperazine SCHEMBL2267453 0.79 PKM (0.44) HRH4HRH3CYP1A2TDP1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US claimed
US-20250066860-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2025-02-27 US disclosed
CN-111868260-B Methods and materials for assessing and treating cancer 约翰斯霍普金斯大学 2025-02-21 CN disclosed
US-12195803-B2 Methods and materials for assessing and treating cancer THE JOHNS HOPKINS UNIVERSITY (US) 2025-01-14 US disclosed
CN-114761383-A Sulfonamide derivatives and uses thereof 诺瑟拉有限公司 2022-07-15 CN disclosed
US-20200377956-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2020-12-03 US disclosed
CN-111868260-A Methods and materials for assessing and treating cancer 约翰斯霍普金斯大学 2020-10-30 CN disclosed
EP-3665308-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER The Johns Hopkins University (US) 2020-06-17 EP disclosed
US-20190256924-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2019-08-22 US disclosed
WO-2019067092-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2019-04-04 WO disclosed
US-20110201657-A1 AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-08-18 US disclosed
WO-2011000490-A2 SYNTHESIS OF IONIC LIQUIDS MERCK PATENT GMBH (DE) 2011-01-06 WO disclosed
US-7863294-B2 Heterocycle derivatives as histone deacetylase (HDAC) inhibitors INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-01-04 US disclosed
US-20090275619-A1 Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-11-05 US disclosed
US-20090176765-A1 Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) MSD ITALIA S.R.L. (IT) 2009-07-09 US disclosed
US-20090048228-A1 Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US disclosed
EP-0958378-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY Rapigene, Inc. (US) 1999-11-24 EP disclosed
EP-0952228-A2 Compositions and methods for enhancing hybridization specificity Rapigene, Inc. (US) 1999-10-27 EP disclosed
WO-1998013527-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY RAPIGENE, INC. (US) 1998-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048228-A1 Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors HDAC1, HDAC5, HDAC11 HRH4 714/4885HRH3 472/4885CYP1A2 2172/4885
US-20090275619-A1 Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors PARP1, PARP3, PARP2 HRH4 3505/4885HRH3 1564/4885CYP1A2 2226/4885
US-20110201657-A1 AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS PARP1, PARP3, PARP2 HRH4 3505/4885HRH3 1564/4885CYP1A2 2226/4885
US-20090176765-A1 Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) PARP1, PARP2, PARP3 HRH4 2937/4885HRH3 1527/4885CYP1A2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.